Previous 10 | Next 10 |
NEWARK, Calif., May 20, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced results related to its seladelpar cl...
The Differentiation In the last 12 months, CymaBay ( CBAY ) has potentially established seladelpar, its lead drug asset, as an improved second-line therapy for PBC based on the 52-week Phase 2b data. As a small cap ($849M) biopharma, CymaBay is making liver therapeutic waves with seladelpa...
CymaBay Therapeutics (NASDAQ: CBAY ) initiated with Buy rating and $21 (70% upside) price target at Citigroup. Shares up 1% premarket. More news on: CymaBay Therapeutics, Inc., MannKind Corporation, Pieris Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 104 weeks of public selections as part of this ongoing live forward-testing. ...
CymaBay Therapeutics ( CBAY ) : The company announced first quarter financial results, with management highlighting the fact that enrollment was completed one quarter ahead of schedule in the phase 2b study of seladelpar in NASH patients (52-week, dose-ranging trial). Topline data for chang...
CymaBay Therapeutics, Inc. (CBAY) Q1 2019 Results Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Dan Menold – Vice President of Finance Sujal Shah – Chief Executive Officer Chuck McWherter – Chief Scientific Officer Pol Boudes –...
CymaBay Therapeutics (NASDAQ: CBAY ): Q1 GAAP EPS of -$0.37 misses by $0.03. More news on: CymaBay Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
NEWARK, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the ...
NEWARK, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that multiple abstracts related to its seladelpar clinical development program for the treatment of primary biliary cholangitis (PBC) will be presented in poster sessions at Digestive...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 102 weeks of public selections as part of this ongoing live forward-testing. In...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...